Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALT-P7
- Development stage
- Phase 1
- Lead developer
- Alteogen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ALT-P7 is an antibody-drug conjugate (ADC) developed by Alteogen for the treatment of HER2-positive metastatic breast cancer. It is composed of a trastuzumab biobetter antibody (HM2) conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) using Alteogen's proprietary NexMab site-specific conjugation technology. This technology is designed to produce a more homogeneous ADC with improved stability and a better therapeutic index compared to conventional random conjugation methods. ALT-P7 targets the HER2 receptor on cancer cells, where it is internalized and releases its cytotoxic payload to induce cell death via microtubule disruption and subsequent apoptosis.
- Other names
- HM2-Drug ConjugateHM-2-Drug ConjugateHM 2-Drug Conjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ALT-P7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALT-P7.